Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 90Triple Negative Breast Neoplasms 18Stomach Neoplasms 14Inflammatory Breast Neoplasms 12Esophageal Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Testicular Neoplasms 3Pancreatic Neoplasms 3Lymphoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Hepatocellular 2Carcinoma, Adenoid Cystic 2Breast Neoplasms, Male 2pCR Rate 1Women With Primary Breast Cancer 1Upper Tract Urothelial Carcinoma 1Unilateral HER2 Positive Breast Cancer 1Thymoma 1Testicular Germ Cell Tumor 1Small Cell Lung Cancer Extensive Stage 1Rare Tumour 1Prostatic Neoplasms 1Primary Breast Cancer 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Epirubicin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HR+/HER2- Breast Cancer × Epirubicin × Clear all
NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
357 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡